<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406704</url>
  </required_header>
  <id_info>
    <org_study_id>KCMC-04-14</org_study_id>
    <nct_id>NCT01406704</nct_id>
  </id_info>
  <brief_title>Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH</brief_title>
  <official_title>Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic
      acid, antioxidant on patients with pathologically proved NASH (non-alcoholic
      steato-hepatitis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duration: 24 week-intervention Study Group: Four arms

        -  Control: no intervention

        -  Rosiglitazone: rosiglitazone (8 mg/day)

        -  alpha-lipoic acid: alpha-lipoic acid (1800 mg/day)

        -  Rosiglitazone/alpha-lipoic acid: combination of rosiglitazone (8 mg/day) and
           alpha-lipoic acid (1800 mg/day)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    because of withdrawal of Avandia sale due to its risks outweigh its benefits
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological evaluation</measure>
    <time_frame>24 weeks</time_frame>
    <description>NASH Histological scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomechanical measurement</measure>
    <time_frame>24 weeks</time_frame>
    <description>liver function test, insulin resistance</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>NASH (Non-alcoholic Steato-hepatitis)</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosiglitazone (8 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alpha-lipoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alpha-lipoic acid (1800 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone/alpha-lipoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Rosiglitazone (8 mg/day)</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-lipoic acid</intervention_name>
    <description>alpha-lipoic acid (1800 mg/day)</description>
    <arm_group_label>alpha-lipoic acid</arm_group_label>
    <other_name>Thioctic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone/alpha-lipoic acid</intervention_name>
    <description>combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)</description>
    <arm_group_label>Rosiglitazone/alpha-lipoic acid</arm_group_label>
    <other_name>Avandia/Thioctic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patients with pathologically proved NASH (non-alcoholic steato-hepatitis)

        Exclusion Criteria:

          -  alcohol consumption &gt; 20g/day

          -  viral hepatitis B and C

          -  autoimmune hepatitis

          -  Wilson's disease

          -  hemochromatosis

          -  alpha-1 antitrypsin deficiency

          -  breast-feeding or pregnant females

          -  subjects planning to become pregnant

          -  severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or
             psychological problems)

          -  those not consenting for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun Ho Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <verification_date>January 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>August 18, 2011</last_update_submitted>
  <last_update_submitted_qc>August 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kun Ho Yoon/principal investigator</name_title>
    <organization>Seoul St. Mary's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

